ASCO 2022 | Updates from the DETERMINATION trial: RVD vs. autoSCT in patients with multiple myeloma
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the DETERMINATION trial (NCT01208662) evaluating the use of lenalidomide, bortezomib, and dexamethasone versus high-dose treatment with autologous stem cell transplantation (autoSCT) in patients with multiple myeloma. Dr Richardson first highlights some results from this trial, including the progression-free survival (PFS) observed in patients and the importance of transplant in controlling event-free survival (EFS). Dr Richardson then discusses the toxicities observed and further highlights other therapies changing the myeloma treatment landscape, including quadruplet therapies, monoclonal antibodies, CAR-T therapy, and bispecific T-cell engagers (BiTEs). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
